Clinical Trial: REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)

U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07887750) titled 'REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)' on Oct. 14.

Brief Summary: This study will test a new experimental study drug called REGN9220 with a Regeneron drug called odronextamab (both called "study drug") to see if it can help treat people with aggressive BCNHL that has either come back/gotten worse or has not responded to previous treatment.

The study is looking at:

* What side effects REGN9220 might cause when given with odronextamab

* How well REGN9220 works when given with odronextamab

* How much REGN9220 is in the blood at di...